MD Anderson Cancer Center

Site:	MD Anderson Cancer Center	Go to their website
Address:	1515 Holcombe Blvd.
City:	Houston
State:	TX
Zip:	77030
Country:	USA

65 trials at this site

Phase [desc]	Trial	Trial Status	Site Status	Drug	NCT#
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
2	Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)	Withdrawn	Closed	Nilotinib	NCT01270893
2	A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST	Completed	Closed	Imatinib + AT13387	NCT01294202
2	Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors	Completed	Not yet activated	Linsitinib (OSI-906)	NCT01560260
2	A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors	Ongoing, but not recruiting	Closed	MEK162 + BYL719	NCT01449058
2	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	Completed	Closed	Dovitinib	NCT01831726
2	Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors	Active, not recruiting	Active	LOXO-101	NCT02576431
2	Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes	Active, not recruiting	Closed	Durvalumab + Tremelimumab	NCT02815995
2	Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study	Active, not recruiting	Closed	CB-839	NCT03872427
2	Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)	Withdrawn	Not yet activated	Ripretinib plus Binimetinib	NCT05080621
2	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	Recruiting	Active	Belzutifan	NCT04924075
2	Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Closed	Rogaratinib	NCT04595747
2	Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.	Active, not recruiting	Closed	Regorafenib (SDH)	NCT06087263
2	KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting	Recruiting	Active	KQB198 + Imatinib	NCT07406633
1	Phase I Trial of PX-478	Completed	Closed	PX-478	NCT00522652
1	Phase I Trial of Oral PX-866	Ongoing, but not recruiting	Closed	PX-866	NCT00726583
1	Continuous Dosing of Regorafenib in Patients With Advanced Malignancies	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01117623
1	Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.	Ongoing, but not recruiting	Closed	AUY922	NCT00526045
1	A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors	Ongoing, but not recruiting	Closed	R1507	NCT00560144
1	Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma	Ongoing, but not recruiting	Closed	PXD101	NCT00413075

MD Anderson Cancer Center

65 trials at this site

First | Previous | Page 2 of 4 | Next | Last